City of Hope, an independent research and cancer and diabetes treatment center, recently formed an alliance with biomedical research institute Translational Genomics Research Institute (TGen), based in Phoenix, to enhance precision medicine efforts for patients.
The alliance allows the groups to share information in terms of research and patient care. City of Hope will provide a clinical setting to help advance the scientific discoveries made by TGen.
City of Hope is a pioneer in the fields such as bone marrow transplants, some tumor issues and hematologic malignancies. TGen applies genomic analysis to cancer drug development.
“This alliance will enable us to fully deploy genomic-enabled medicine within a modern health care system to create a disruptive change in the practice of medicine," Jeffrey Trent, president and research director for TGen, said. "Our aim is to not only navigate this changing field, but lead it.”
City of Hope and TGen aim to transform the entire process of prevention, diagnosis and treatment of cancer and other life-threatening diseases. The alliance will shorten the amount of time between medical research discoveries and cures.
“Patients want choices and access to the newest and most advanced care available,” Robert Stone, president and chief executive officer of City of Hope, said. “City of Hope and TGen share a common vision for improving patient outcomes, and our collaboration will speed cancer cures by rapidly advancing discoveries to define high-risk populations, identifying targets for prevention and treatment, and promoting initiatives that close health equity gaps.”
TGen will remain a Phoenix-based nonprofit and will join the City of Hope system as a subsidiary.